drugset / Trial / NCT05823701
Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of CAGM regimen in R/R DLBCL patients and to provide a safe and more effective approach for R/R DLBCL patients.
Timeline
- Start
- 2022-09-30
- Primary completion
- 2023-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 100 mg | Subcutaneous |
| Subject | Mitoxantrone hydrochloride liposome | Unknown | 20 mg/m2 | Intravenous |
| Subject | Obinutuzumab | Monoclonal antibody | 1000 mg | Intravenous |
| Subject | Tucidinostat | Small molecule | 20 mg | Oral |